Δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders

Miao Xu,1,7* Ke Liu,1* Manju Swaroop,1 Forbes D. Porter,2 Rohini Sidhu,3 Sally Finkes,3 Daniel S. Ory,3 Juan J. Marugan,1 Jingbo Xiao,1 Noel Southall,1 William J. Pavan,4 Cristin Davidson,5 Steven U. Walkley,5 Alan T. Remaley,6 Ulrich Baxa,7 Wei Sun1, John C. McKew,1 Christopher P. Austin,1 Wei Zheng†

1National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20892; 2Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892; 3Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, MO 63110; 4Genetic Disease Research Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892; 5Sidney Weisner Laboratory of Genetic Neurological Disease, Rose F. Kennedy Center, Albert Einstein College of Medicine, Bronx, NY 10461; 6Laboratory of Lipoprotein Metabolism, National Heart, Lung and Blood Institute, Bethesda, MD 20892; 7Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 8Electron Microscopy Laboratory, National Cancer Institute, NIH, Bethesda, MD 20892.

*These authors contributed equally to this work
†To whom correspondence should be addressed:
Wei Zheng, Ph.D.
National Center for Advancing Translational Sciences, NIH
9800 Medical Center Drive, MSC: 3370
Bethesda, MD 20892-3370
Email: wzheng@mail.nih.gov
Tel.: (301)827-6727

Running title: Reducing storage in lysosomal diseases through exocytosis

Keywords: Δ-Tocopherol, Niemann Pick disease type C1, Wolman disease, Lysosomal storage diseases, lysosomal exocytosis.

Background: Niemann Pick disease Type C and Wolman diseases are caused by mutations in genes responsible for intracellular cholesterol processing and trafficking.

Results: Δ-tocopherol reduces lysosomal accumulation of cholesterol and other lipids potentially through enhancement of lysosomal exocytosis.

Conclusion: Δ-tocopherol is a novel lead compound for drug development to treat lysosomal storage diseases.

Significance: Lysosomal exocytosis may represent a new drug target broadly applicable to lysosomal storage diseases.
SUMMARY

Niemann-Pick disease type C (NPC) and Wolman disease are two members of a family of storage disorders caused by mutations of genes encoding lysosomal proteins. Deficiency in function of either the NPC1 or NPC2 protein in NPC disease, or lysosomal acid lipase in Wolman disease results in defective cellular cholesterol trafficking. Lysosomal accumulation of cholesterol and enlarged lysosomes are shared phenotypic characteristics of both NPC and Wolman cells. Utilizing a phenotypic screen of an approved drug collection, we found that δ-tocopherol effectively reduced lysosomal cholesterol accumulation, decreased lysosomal volume, increased cholesterol efflux, and alleviated pathological phenotypes in both NPC1 and Wolman fibroblasts. Reduction of these abnormalities may be mediated by a δ-tocopherol-induced intracellular Ca^{2+} response and subsequent enhancement of lysosomal exocytosis. Consistent with a general mechanism for reduction of lysosomal lipid accumulation, we also found that δ-tocopherol reduces pathological phenotypes in patient fibroblasts from other lysosomal storage diseases including NPC2, Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (MPS IIIB), and Tay-Sachs. Our data suggest that regulated exocytosis may represent a potential therapeutic target for reduction of lysosomal storage in this class of diseases.

INTRODUCTION

Niemann-Pick Disease type C (NPC) disease is caused by mutations in either the NPC1 or NPC2 gene, encoding two distinct lysosomal cholesterol binding proteins (1,2). The NPC cellular phenotype is characterized by lysosomal accumulation of unesterified cholesterol and other lipids, resulting from impaired cholesterol export from the late endosomal and lysosomal compartments (2,3). Wolman disease is caused by mutations in the gene encoding lysosomal acid lipase (LAL). Deficiency of LAL function results in two distinct disease phenotypes that accumulate both cholesteryl ester and triglycerides. The early onset form is known as Wolman disease and the late onset form as cholesteryl ester storage disease (3,4). Enlarged lysosomes are a common cellular phenotype for both NPC and Wolman diseases.

Cholesterol is an essential component of cellular membranes and is central to maintaining both membrane integrity and fluidity, as well as regulating membrane protein function, cell signaling and ion permeability (5). In addition, cholesterol is the precursor molecule for synthesis of cellular components such as bile acids, oxysterols, and steroid hormones. Cholesterol homeostasis is tightly regulated at both the cellular and whole-body levels (6). While the homeostasis of serum and tissue cholesterol has been well defined, many details of intracellular cholesterol regulation and trafficking are still to be elucidated. Esterified cholesterol contained in low-density lipoprotein (LDL) enters a cell via endocytosis.
Upon LDL entry into the late endosome/lysosome, LAL hydrolyzes fatty acyl chains from cholesteryl esters to liberate unesterified cholesterol that is transported out of the late endosome/lysosome involving NPC1 and NPC2 proteins (6-8). The precise mechanism and pathway of cholesterol trafficking from the lysosome remains unclear, though it has been established that unesterified cholesterol moves to the endoplasmic reticulum (ER) for re-esterification or utilization by the cell, and to the trans-Golgi network and/or plasma membrane for efflux from the cell (5,9).

Currently, there are no FDA-approved therapies for either NPC disease or Wolman disease. However, miglustat, originally approved as a substrate reduction drug for Gaucher disease, has been approved in the EU for the treatment of NPC1 disease by European Agency for the Evaluation of Medicinal Products (EMEA). Therapeutic strategies that have been explored include reduction of lysosomal lipid burden, augmentation of mutant protein expression, or replacement of mutant proteins in lysosome (10).

Enzyme replacement therapy (ERT), which has been successfully used to treat selected lysosomal storage diseases, was studied in the mouse model of Wolman disease but is not clinically approved (11). A protein replacement therapy, similar to ERT, would in theory be possible for NPC2 disease, but is not feasible for NPC1 disease because NPC1 is an integral membrane protein. A phenotypic screen of a compound collection recently identified compounds that reduced filipin staining in NPC1 fibroblasts (12), and several laboratories have reported lead compounds including 2-hydroxypropyl-β-cyclodextrin and HDAC inhibitors that reduce cholesterol accumulation (12-15). A recent report revealed that the cyclodextrin’s mechanism of action to reduce cholesterol accumulation in NPC1 mutant cells is through induction of exocytosis (16). Here we report the identification of δ-tocopherol (δ-T) in a phenotypic screen of an approved drug library that significantly reduces lysosomal cholesterol accumulation in NPC1 fibroblasts. Following δ-T treatment, the enlarged acidic endosomal/lysosome compartment was dramatically reduced, and the pathological phenotype of NPC1 cells, as determined by ultrastructural analysis, was alleviated. Similar effects of δ-T were also observed in Wolman fibroblasts. The mechanism of action for δ-T was linked to increase in cytosolic Ca²⁺, correction of the lysosomal Ca²⁺ deficiency, and enhancement of lysosomal exocytosis. The effect of δ-T also extended to patient-derived fibroblasts from other lysosomal storage diseases, including Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A (NPA), NPC2, Sanfilippo type B (MPS IIIB), and Tay-Sachs. The results indicate that the enhancement of lysosomal exocytosis may represent a new therapeutic strategy for the drug development that may be widely applicable to lysosomal storage diseases.

**EXPERIMENTAL PROCEDURES**

*Materials* - Hoechst and LysoTracker Red dye were purchased from Invitrogen (Carlsbad, CA).
Filipin dye was obtained from Sigma-Aldrich (St. Louis, MO). α-Tocopherol and δ-tocopherol were purchased from Sigma-Aldrich and purified by HPLC to purity greater than 99%. β-Tocopherol (racemic), α-tocotrienol, β-tocotrienol, and γ-tocotrienol were obtained from Sigma-Aldrich in analytical standard grade (purity ≥ 97%). γ-Tocopherol and δ-tocotrienol were purchased from ChromaDex (Irvine, CA) in vitamin reference standard grade (purity > 96%). The 96-well, 384-well and 1536-well plates were purchased from Greiner Bio-One (Monroe, NC). Human skin fibroblast cell lines (Table S1) were purchased from the Coriell Cell Repository (Camden, NJ) including control cell line (GM05659), NPC1 (GM03123), NPC2 (GM17910), Wolman (GM11851), Batten (GM16485), Farber (GM20015), Fabry (GM00107), Niemann-Pick Disease type A (GM16195), Sanfilippo type B (GM02552), and Tay-Sachs (GM00221). The GM03123 fibroblasts were utilized mainly in the NPC1 experiments unless specifically indicated. The NPC25 (c.2979dupA, p.N701K) skin fibroblast line was derived from a NPC1 patient evaluated under an NICHD IRB approved clinical protocol, and obtained with consent.

Cell culture - Both human fibroblasts and baby hamster kidney (BHK) cells were cultured in DMEM medium (Invitrogen, cat# 11995-040) supplemented with 10% fetal bovine serum (FBS), 100 unit/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 5% CO2 at 37°C.

Approved drug collection - A collection of 2,816 compounds approved drugs that were dissolved in DMSO solution as 10 mM stock solution. were set up as described previously (17). The compounds were serially diluted 1:5 in 384-well plates for seven concentrations and formatted into 1,536-well plates at 5 μl/well as the compound source plates. In the primary screen, 23 nl of compounds in DMSO solution was transferred using a Pintool station (Klaypsys, San Diego, CA) to 1536-well assay plates containing 5 μl/well cell culture medium. The final concentrations of compounds ranged from 1.32 nM to 46 μM.

Amplex-Red cholesterol assay - Total cholesterol in patient cells was measured by the Amplex-Red Cholesterol Assay Kit (Invitrogen). The unesterified cholesterol was determined using the same kit without the enzyme acid lipase. Esterified cholesterol was determined as the difference between the total and unesterified cholesterol values. The cells were seeded in black, tissue culture-treated 1536-well plates at 800 cells/well in 5 μl medium by a Multidrop Combi dispenser (Thermo Scientific, Waltham, MA) and cultured for 24 hr. The assay plates were added with 23 nl/well of compound DMSO solution using a Pintool station (Klaypsys, San Diego, CA) and cultured for 3 days. The cells were washed twice using a centrifugation method in which the inverted plates were placed on a stack of paper towel and centrifuged at 800 rpm for 1 min followed by addition of 7 μl/well PBS (added gently with a 45 degree angled liquid dispenser (Klaypsys)). The cholesterol assay mixture from the kit was added at 2.5 μl/well and incubated for 1 hr at 37°C. The resulted fluorescence intensity
was measured with excitation of 560 (±10) and emission of 590 (±10) in a fluorescence plate reader (Tecan, Durham, NC).

**Cholesterol analysis by liquid chromatography–mass spectrometry (LC-MS)** - Cell pellets were collected from 100-mm dishes and washed once with 10 ml PBS. Proteins were assayed using the BCA kit (Sigma-Aldrich) and lipids were extracted by modified Bligh and Dyer procedure (18) from the cells. Internal standards were added based on protein concentration that included N12:0 sphingomyelin, D7-cholesterol, 17:0 cholesteryl ester (Avanti Polar Lipids, Inc). The lipid extract was derivatized to convert cholesterol and its ester into acetate for facilitating ionization using direct infusion mass spectrometric assay. The derivatization was performed by treating the dried crude lipid extract with solutions of 1M acetic acid with1M DMAP in chloroform and 1M EDC in chloroform at 50°C for 2 hours. The derivatized product was extracted with hexane and analyzed by direct infusion mass spectrometric assay with 5 % ammonium hydroxide for facilitating ionization.

A triple-quadrupole mass spectrometer equipped with an electrospray was used for analysis of lipids in positive mode. Sphingomyelins, cholesterol and cholesteryl esters were detected by neutral loss scan of 213 (collision energy: 50 V), neutral loss scan of 77 (collision energy: 14 V) and precursor ion scan of m/z 369 (collision energy: 14 V) respectively. Data processing of mass spectrometric analyses including ion peak selection, data transferring, peak intensity comparison and quantification was conducted using self-programmed Microsoft Excel macros (19).

**Cytotoxicity assay** - In an initial experiment, we found that commercially-available vitamin E isoforms were cytotoxic at the similar concentrations required for their pharmacological effect. The ATP content assay kit (Promega or PerkinElmer) was applied to monitor the compound cytotoxicity. Cells were seeded in white solid 96-well or 1536-well plates and treated with compounds as described above for the cholesterol assay. On the experimental day, 3 μl/well assay mixture (prepared according to the manufacturer’s instruction) was added to the assay plates followed by incubation at RT for 10 min. The luminescence signal was determined in the luminescence mode of a Tecan multifunction plate reader.

**Filipin staining** - Cells were seeded at 1500 cells/well in 100 μl medium in black/clear bottom, tissue culture treated 96-well plates and cultured for 24 hr. After addition of compound solution, the plates were cultured for 3 days. The cells were washed twice with PBS and fixed by 100 μl/well 3.2% formaldehyde at room temperature (RT) for 30 min. After washing with PBS two times, the cells were stained with 100 μl/well 50 ng/ml filipin (freshly-dissolved in DMSO at 10 mg/ml and then diluted in PBS) at RT for 1 hr. The plates were stored at 4°C after washing two times with PBS before the imaging analysis. On the day of imaging experiment, cells were stained with 100 μl/well of 2 μM of CellMask-Red dye (Invitrogen,
H32711) in PBS at RT for 1 hour. The plates were imaged using an Incell2000 automated fluorescence plate imaging reader (GE Healthcare) with a 20 × or 40 × objective. DAPI filter set (Ex = 360 ± 20 nm and Em = 460 ± 20 nm) and TRITC filter set (Ex = 545 ± 20 nm and Em = 593 ± 20 nm) were used to visualize filipin and CellMask staining, respectively.

**Nile-red staining** - The cells were cultured and treated as described above. On the experimental day, cells were washed two times with PBS and live-stained with 1 µM Nile-red dye solution (prepared in cell culture medium) at 100 µl/well followed by an incubation at 37 °C for 10 min. After washing twice with PBS, the cells were fixed in 3.2% paraformaldehyde in PBS at 100 µl/well for 1 hr at RT. The nuclear staining was carried out by an addition of 100 µl/well 1 µg/ml Hoechst 33342 (Invitrogen) in PBS and incubation at RT for 30 min. The plate was washed twice with PBS and the images were measured in Incell2000 imaging plate reader with a FITC filter set (Ex = 480 ± 20 nm and Ex = 525 ± 36 nm) for the neutral lipids (cholesteryl esters and triglycerides) and a DAPI filter set for Hoechst nuclear staining.

**Bodipy-lactosylceramide (bodipy-LacCer) staining** - The cells in 96-well assay plate were prepared as described above, incubated with 100 µl/well bodipy-LacCer dye (Invitrogen, # B-34402) in 1% FBS DMEM and incubated at 37°C for 1 hr followed by plate washing with HMEM buffer (13.8 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 2 mM glutamine, 0.4 mM KH₂PO₄, 0.18 mM Na₂HPO₄, 1X MEM vitamins and 1X MEM amino acids at pH 7.4). The cells were rinsed with cold HMEM buffer containing 5% fatty acid-free BSA and back exchanged at 11°C six times over 60 min as described previously (20). Images were immediately taken in the InCell2000 imaging plate reader with the DAPI filter set.

**LysoTracker dye staining** - The assay was optimized to visualize the enlarged lysosomes by applying appropriate concentration of LysoTracker dye in which the control cells exhibited minimal staining while the NPC1 or other disease cells showed significant staining. The cells were cultured and treated as described above. On the experimental day, cells were live-stained with 100 µl/well 50 nM LysoTracker-Red DND-99 dye (Invitrogen, # L-7528) in medium at 37°C for 1 hr followed by plate washing twice with PBS. The plate was used for image analysis of live cell staining or was fixed in 100 µl/well 3.2% formaldehyde for 1 hr and washed two times with PBS. The nuclear staining was performed by an addition of 100 µl/well 1 µg/ml Hoechst 33342 (Invitrogen) in PBS and incubation at RT for 30 min. After washing twice with PBS, the plates were stored at 4°C until imaging analysis. DAPI filter set and TRITC filter set in the Incell2000 imaging plate reader were used to visualize Hoechst nuclear staining and LysoTracker staining, respectively.

**Electron Microscopy** - Fibroblast cells were seeded in 6-well plates in 5 ml medium at 150,000 cells/well and cultured for 1 day in the presence or
absence of compounds. Cells were fixed in 2% glutaraldehyde, 0.1 M cacodylate buffer, pH 7.2 for 1 hour at room temperature and then stored at 4°C until TEM analysis was performed. The cells were post fixed in 1% osmium tetroxide in the same buffer for 1 hour and en bloc stained with 0.5% uranyl acetate in 0.1 M acetate buffer, pH 4.2. The cells were then dehydrated in graded ethanol solutions (35%, 50%, 70%, 95% and 100%) and infiltrated overnight in epoxy resin (Poly/Bed 812, Polysciences). After adding fresh pure resin the cell plates were cured for 72 h in 55°C. After removing the polystyrene plates, suitable areas for thin sectioning were selected, cut out with a jewelry saw and glued onto empty resin stubs. About 70 nm thin sections were cut on an ultramicrotome (Leica EM UC6) and mounted on naked copper grids. The thin sections were double stained (uranyl acetate and lead citrate), examined in a Hitachi H-7650 transmission electron microscope, and images were taken using an AMT CCD camera (21).

Western blot analysis - Cell lysates were prepared and protein concentrations were determined as described above. Samples were heated at 65°C for 10 min before being resolved by SDS-PAGE under reducing conditions. Proteins were transferred to PVDF membranes (Bio-Rad Laboratory) using either Criterion Blotter (Bio-Rad Laboratory) or iBlot dry blotting devices (Invitrogen). For NPC1 and HMG-CoA reductase detection, rabbit polyclonal antibodies against NPC1 (Abcam, # ab36983, 1:2000) or HMG-CoA reductase (Millipore, # 07-457, 1:1000) were used, respectively. A peroxidase-conjugated donkey anti-rabbit IgG (Santa Cruz) was used as secondary antibody at a 1:500 dilution. Flotillin, an exosome marker, was determined using a method described previously (16). Briefly, the media from cells in 100 x 20 mm dishes treated with 40 μM δ-T or positive controls, 2% HPBCD and 1 μM ionomycin for 1 hr at 37°C were collected and centrifuged at 100,000 g for 1 hr for isolation of exosomes. The resulting exosomes were resuspended in 20 mM Tris-HCl buffer (pH 8.0) and sonicated in a bath sonicator to yield the final samples for Western blot analysis as described above. A mouse anti-flotillin 2 antibody (BD Biosciences) was used for the detection of flotillin in the exosomes. Cells were lysed and the cell lysates were collected for the determination of GAPDH used for normalization of proteins in each sample.

\[ ^3\text{H}-\text{Cholesterol efflux assay} \] - Efflux of cholesterol from BHK cells was performed as previously described (22). Briefly, BHK cells and BHK cells stably transformed with ABCA1, ABCG1 and SR-BI were radiolabeled with \(^3\text{H}\)-cholesterol (1 μCi/mL) in medium for 24 hr. After washing three times with DMEM, DMEM medium containing 50 μg/ml HDL was added and cultured for 18 hr. The radioactivity in the HDL containing medium and cell lysate were determined. The percent of total radiolabeled cholesterol effluxed into the media was calculated by dividing by the sum of the radioactive counts remaining in the cells after the efflux period plus the counts in medium.
Intracellular and lysosomal Ca\(^{2+}\) measurements - Intracellular cytosolic Ca\(^{2+}\) concentration was measured fluorescently using a Fluo-8 dye kit (ATT Bioquest, Sunnyvale, CA) as described previously. Briefly, fibroblasts were cultured at 2500 cell/well in 20 \(\mu\)l medium in black, clear bottom 384-well plates for 24 hr at 37°C. The calcium dye mixture was added at 20 \(\mu\)l/well and incubated at 37°C for 30 min followed by room temperature for 30 min. The plates were then placed into a fluorescence kinetic plate reader (\(\mu\)Cell, Hamamatsu, Hamamatsu City, Japan). The basal fluorescence intensity was recorded 10 times at 1Hz for 10 seconds and the compound (\(\delta\)-T or \(\alpha\)-T) was then added at 20 \(\mu\)l/well inside the instrument followed by additional reading at 1Hz for 5 min. The results were normalized to the average basal fluorescence intensity in ratio and the peak response (Max.) was used for the result calculation. The lysosomal Ca\(^{2+}\) induced by Gly-Phe \(\beta\)-naphthylamide (GPN) was measured similarly as that for cytosolic Ca\(^{2+}\) except 200 nM GPN was added instead of \(\delta\)-T or \(\alpha\)-T after the measurement of basal fluorescence intensity that released lysosomal Ca\(^{2+}\).

Endocytosis and lysosomal pH measurement – Endocytosis was measured using a fluorescence labeled dextran dye (pHrodo™ dextran, catalog # P10361, Invitrogen) that enters cell through endocytosis. This dye emits fluorescent signal at the acidic pH while exhibiting minimal fluorescence signal at neutral pH. The fibroblasts in 96-well plates were treated with 40 \(\mu\)M \(\delta\)-T or 80 \(\mu\)M \(\alpha\)-T for 24 hrs and incubated with 20 mg/ml pHrodo dye for 16 hrs. The live cell imaging was carried out after a cell wash with PBS with an excitation of 560 nm and emission of 590 nm. Chlorpromazine, a known inhibitor of endocytosis was used as a positive control (final concentration of 5 \(\mu\)g/ml). The lysosomal pH was determined using a fluorescent LysoSensor dextran dye (catalog # L-22460, Invitrogen) that emits strongly at 530 nm in acidic pH environment and at 450 in neutral pH. The fibroblasts in 96-well plates were treated with 40 \(\mu\)M \(\delta\)-T for 24 hrs and incubated with the pH indicator dye for 16 hrs. The images were taken using Incell2000 (GE healthcare) with an excitation of 360 nm, emission-1 of 530 and emission-2 of 450 nm.

Measurement of \(\beta\)-hexosaminidase (HEXB) release - Fibroblasts were cultured in 24-well plates at 30,000 cells/well in 0.4 ml medium for one day at 37°C. After being washed twice with assay buffer (DMEM with 2mM D-mannose 6-phosphate sodium salt), the cells with 0.4 ml/well assay buffer were incubated at 37°C with 0.2 ml/well compound in assay buffer. At 5, 10, 20, 30 and 40 min time points, 30 \(\mu\)l of assay buffer from each well in the 24-well plate were aliquoted into a 96-well black plate. The rest of assay buffer in the 24-well plate was discarded followed by addition of 0.6 ml 1% Triton-X100 in dH\(_2\)O to lyse the cells. After incubation at 37°C for 30 min, 6 \(\mu\)l/well cell lysate were added to the 96-well plate with 24 \(\mu\)l assay buffer followed by 90 \(\mu\)l/well 2.25 mM HEXB substrate, 4-
Methylumbelliferyl N-acetyl-β-D-glucosaminide (Sigma-Aldrich, # M2133), in a 25 mM citric acid buffer at pH 4.5. The 96-well plate was then measured in the Tecan fluorescence plate reader (Ex = 365 ± 20 nm and Em = 460 ± 20 nm) after 1 hr incubation at 37°C and addition of 100 µl/well stop solution (1 M glycine and 1 M NaOH at pH 10.5).

Data analysis and statistical analysis - The compound library screen data was analyzed using software developed internally at NIH Chemical Genomics Center. Concentration-response curves were analyzed and EC₅₀ values (mean ± SD) calculated using Prism software (GraphPad, San Diego, CA). Results in figures are expressed as mean of triplicates ± SD. The statistical significance of differences was determined by a two-tailed single-factor analysis or variance (ANOVA) or Student’s t test. A P value of ≤ 0.05 was considered significant.

RESULTS

High throughput screen and identification of cholesterol reduction activity of δ-T - Skin fibroblasts derived from NPC1 patients demonstrate profound and reproducible cholesterol accumulation in late endosomes and lysosomes and, therefore, provide a robust cellular model of NPC1 disease (12,16). Using a phenotypic screen of 2,816 approved drugs with a biochemical assay to measure unesterified cholesterol, δ-T was identified as a lead compound that dramatically reduced cellular cholesterol accumulation in NPC1 fibroblasts. δ-T is one of eight components in natural vitamin E that consists of a mixture of four tocopherols and four tocotrienols. All eight isoforms reduced unesterified cholesterol accumulation in a concentration dependent manner with EC₅₀ values ranging from 13.2 µM for δ-T to 58.6 µM for β-tocopherol (Fig. 1A). A similar reduction of cholesterol accumulation was observed in NPC2 fibroblasts (Fig. S1A). Cholesterol accumulation in NPC1 fibroblasts was not affected by lovastatin, an inhibitor of cellular cholesterol synthesis, antioxidants Vitamin C and N-Acetyl-Cysteine (NAC), or by vitamin K (Fig. S1B). The cholesterol reducing effect of δ-T in NPC1 cells was confirmed by liquid chromatography-mass spectrometry (LC-MS) analysis (Fig. 1B). In addition to the reduction of unesterified cholesterol, cholesteryl esters were also reduced in the NPC1 cells after the treatment with δ-T (Fig. 1C). To assess the specificity of δ-T to reduce cholesterol accumulation, we tested δ-T in Wolman fibroblasts. Wolman fibroblasts have significantly decreased levels of LAL activity and accumulate cholesteryl ester in lysosomes. We found that δ-T effectively reduced total cholesterol, including cholesteryl ester. δ-T was the most potent (EC₅₀ = 9.0 µM) one among the vitamin E isoforms in the Wolman fibroblasts (Fig. 1A). We also found that all the vitamin E isoforms exhibited no cytotoxicity up to 80 µM in the treatment of control and patient cells for four days except γ-tocotrienol and δ-tocotrienol, which showed cytotoxicity at 80 µM (Fig. S2).
δ-T reduces lysosomal size and corrects ultrastructural pathology of NPC1 and Wolman cells - Filipin is a fluorescent antibiotic that binds to unesterified cholesterol and is commonly used in the diagnosis of NPC1 disease (12,16,23). Treatment of NPC1 fibroblasts with either 40 μM δ-T or 80 μM α–tocopherol (α-T) significantly reduced unesterified cholesterol storage (Fig. 2A), a cellular phenotypic hallmark of NPC1 disease, thus confirming the biochemical findings. Likewise, treatment of Wolman cells with these two compounds significantly reduced staining with Nile Red (Fig. 2B), a dye used to detect nonpolar lipids including cholesteryl ester and triglyceride (24), consistent with the observed reduction of cholesteryl ester accumulation. In addition to accumulation of unesterified cholesterol, NPC1 fibroblasts exhibit lysosomal storage of other lipids, including lactosylceramide (20). Thus, we examined whether the altered trafficking of a fluorescent lactosylceramide analogue, bodipy-lactosylceramide (bodipy-LacCer), could be corrected by δ-T treatment. After treatment with 40 μM δ-T, bodipy-LacCer staining in the NPC1 fibroblasts was dramatically reduced, approaching normal levels (Fig. 2C). These results suggest that the reduction of lysosomal cholesterol accumulation by δ-T may also help to correct the defective trafficking of other lipids in NPC1 cells.

The mixed lipid storage phenotype results in a marked enlargement of lysosomes in the NPC1 and Wolman fibroblasts. Therefore, we next determined whether the enlarged lysosomes in these cells could be reduced by the treatment with δ-T. LysoTracker, a probe which stains the intracellular acidic compartment, has been used to visualize the enlarged endolysosomal compartment in NPC1 cells (20). We found increased LysoTracker staining in both NPC1 and Wolman fibroblasts, as expected. Treatment with either 40 μM δ-T or 80μM α-T significantly reduced LysoTracker staining in both types of fibroblasts (Fig. 3A). Both NPC1 and Wolman fibroblasts have a distinct ultrastructural phenotype that is evident by electron microscopy (25,26). The electron microscopic images exhibited enlarged lysosomes full of lamellated membranes and dense osmiophilic material in NPC1 cells and lipid droplet-like and cleft-like lysosomes in Wolman cells (Fig. 3B). Treatment with 40 μM δ-T significantly reduced the characteristic storage materials in lysosomes of both cell types. Together, these findings demonstrate that the δ-T-mediated cholesterol reduction is associated with alleviation of the disease phenotypes in NPC1 and Wolman cells.

δ-T increases 3H cholesterol efflux - To investigate δ-T’s mechanism of action, we analyzed its effect on the expression of the NPC1 protein and other proteins involved in cholesterol homeostasis. We found that the protein levels of NPC1, HMG-CoA reductase (the rate-limiting enzyme in cholesterol synthesis), and ABCA1 (a sterol transporter) were also not altered by δ-T treatment in NPC1 fibroblasts (Fig. S4). Taken together, these data indicate that the effect of δ-T
is likely not mediated by a change in either de novo cholesterol synthesis or the major transporter involved in cholesterol efflux.

We then examined the effect of tocopherol on \(^{3}\)H-cholesterol efflux in baby hamster kidney (BHK) cells that express ABCA1 at basal level and a BHK cell line with overexpression of ABCA1. We found that 40 \(\mu\)M \(\delta\)-T or 80 \(\mu\)M \(\alpha\)-T increased the efflux of \(^{3}\)H-cholesterol in BHK cells from 9.0 \% to 32.1\% and 27.6 \%, respectively (Fig. 4A). In the ABCA1 overexpressing cells, \(^{3}\)H-cholesterol efflux at the basal level was much higher than that in the parental cells. Treatment with 40 \(\mu\)M \(\delta\)-T or 80 \(\mu\)M \(\alpha\)-T was able to further increase \(^{3}\)H-cholesterol efflux in the ABCA1 overexpressing cells (Fig. 4A). A similar increase in \(^{3}\)H-cholesterol efflux was also observed in cells overexpressing ABCG1 and SR-B1 (Fig. S5). These results suggest that increased cholesterol efflux by \(\delta\)-T may not be mediated by activation of a specific cholesterol efflux pathway, but rather by increasing the general cholesterol efflux through diverse cellular pathways (27).

\(\delta\)-T increases intracellular Ca\(^{2+}\) concentration and ameliorates lysosomal calcium deficiency in NPC1 cells - Increase in the concentration of intracellular Ca\(^{2+}\), an important second messenger, triggers a variety of cellular responses including lysosomal exocytosis. In NPC1 fibroblasts there is a dysregulation of calcium homeostasis, as evidenced by lysosomal Ca\(^{2+}\) deficiency (20). Treatments that compensate for loss of lysosomal Ca\(^{2+}\) (e.g., curcumin) have been reported to reduce cholesterol storage in NPC1 cells (20). To explore whether \(\delta\)-T may similarly exert its effects through changes in intracellular Ca\(^{2+}\), we measured cytosolic calcium levels in both NPC1 and Wolman cells following the treatment with \(\delta\)-T. We found that \(\delta\)-T stimulated a transient increase of cytosolic Ca\(^{2+}\) in both NPC1 and Wolman fibroblasts, as well as in control fibroblasts (Fig. 4B, D and E). In addition, the intracellular Ca\(^{2+}\) response to \(\delta\)-T was independent of extracellular Ca\(^{2+}\) concentration (Fig. S6A), indicating that Ca\(^{2+}\) was released from intracellular storage sites such as the ER in response to \(\delta\)-T. We further studied the effect of \(\delta\)-T on lysosomal Ca\(^{2+}\) released by Gly-Phe \(\beta\)-naphthylamide (GPN) in NPC1 fibroblasts. Consistent with an earlier report (20), lysosomal Ca\(^{2+}\) was reduced in NPC1 cells compared with that in control cells. Treatment of NPC1 fibroblasts with 40 \(\mu\)M \(\delta\)-T for 24 hours significantly increased lysosomal Ca\(^{2+}\) (Fig. 4C) and this effect was not dependent on extracellular Ca\(^{2+}\) (Fig. S6B).

To examine the potential effect of \(\delta\)-T on the endocytosis, we treated the fibroblasts with a fluorescent dextran dye that enters the cells via endocytosis and becomes fluorescent in acidic compartments. We found that the treatment with \(\delta\)-T did not alter the fluorescence intensity of this dye in the endocytic vesicles in both NPC1 and Wolman cells (Fig. 4F), indicating that \(\delta\)-T does not affect the endocytosis. We also measured the pH in late endosomes and lysosomes using a fluorescent pH indicator dye. The treatment with \(\delta\)-T in the fibroblasts did not change the
fluorescence intensity of this pH dye staining in acidic compartments (Fig. S3), suggesting that δ-T does not affect the pH in late endosomes and lysosomes.

δ-T stimulates lysosomal exocytosis in NPC1 and Wolman fibroblasts - 2-hydroxypropyl-β-cyclodextrin has been reported to promote a calcium-dependent lysosomal exocytosis, which offers a potential mechanism for its cholesterol-reducing effect in NPC1 fibroblasts (16). We measured lysosomal exocytosis in δ-T-treated NPC1 and Wolman fibroblasts by determining the activity of β-hexosaminidase (HEXB), a lysosomal enzyme, in the extracellular medium. We found that HEXB activity increased in culture medium after 40 μM δ-T treatment for 24 hours compared with the vehicle treated cells (Fig. 5A, B and C). The increased HEXB activity in culture media stimulated by the 24 hr incubation with δ-T exhibited different kinetics and extent of enzyme release than that induced by the calcium ionophore ionomycin (Fig. S7A-C). The basal levels of HEXB activity in the culture media were also higher in the NPC1 and Wolman fibroblasts compared to that in the wild type cells (Fig. S7D). We then determined the effect of δ-T on the secretion of flotillin 2, an exosome marker, whose secretion was increased by 2-hydroxypropyl-β-cyclodextrin (HPBCD) and ionomycin in fibroblasts (16). Treatment with δ-T stimulated the secretion of flotillin 2 (Fig. 5D), indicative of release of endolysosomal-derived vesicles. We also observed in the electron microscopic images a tendency for the stored materials (in endosomal and lysosomal compartments) to be distributed closer to the plasma membrane and more distant from the nucleus in addition to a reduction in amount of stored materials after treatment with 40 μM δ-T (Fig. 5E). Taken together, these results demonstrate that the pharmacological effect of δ-T may be mediated by the increase of cytosolic Ca2+ and enhancement of lysosomal exocytosis.

δ-T reduces lipid storage and lysosomal enlargement in fibroblasts from patients with other lysosomal storage diseases - Lipid accumulation in the lysosome and enlargement of lysosome size in affected cells are common features of more than 50 lysosomal storage diseases caused by genetic mutations of genes generally encoding lysosomal proteins (28). Despite the heterogeneity in cellular phenotypes among these diseases, lysosomal exocytosis has recently emerged as a new drug target for the potential treatment of these storage disorders (29,30). Based on the data for both NPC1 and Wolman cells, we hypothesized that the pharmacological effect of δ-T on the intracellular Ca2+ and lysosomal exocytosis is a general mechanism for elimination of lysosomal storage. To test this hypothesis we measured the ability of δ-T to decrease acidic/lysosomal compartment size as determined by LysoTracker staining in fibroblasts derived from patients with six other diseases. Lysosomal storage in these fibroblasts consists of ceroid/lipofuscin in Batten (CLN2), globotriaosylceramide in Fabry, ceramide in Farber, sphingomyelin in NPA, partially degraded heparan sulfate in Sanfilippo type B, and GM2
ganglioside in Tay-Sachs (Table S1). Whereas untreated fibroblasts showed increased LysoTracker staining, indicating the enlarged lysosomes (Fig. 6A and B), treatment with 40 μM δ-T significantly reduced the LysoTracker staining in all six fibroblast cell lines studied (Fig. 6A and B). The reduction of acidic cellular compartments by δ-T treatment is consistent with decreased intracellular storage that was confirmed by alleviation of the ultrastructural pathology (Fig. 6C and D). Thus, the amelioration of lysosomal pathology by δ-T, initially demonstrated in NPC1 and Wolman cells, can be generalized to other lysosomal storage diseases.

DISCUSSION

Exocytosis is a housekeeping function responsible for the secretion of hormones, cytokines, and neurotransmitter in secretory cells. In response to a transient increase of cytosolic Ca^{2+}, secretory vesicles move towards the plasma membrane, fuse with the membrane, and then expel the luminal contents into the external cellular environment. Exocytosis in nonsecretory cells plays an important role in plasma membrane repair (31), bone resorption (30), cycling/recycling proteins to plasma membrane (32), pathogen invasion (33), neurite outgrowth (34), and cellular clearance (29,35). Lysosomes, which are the most important exocytic organelle in nonsecretory cells, release their contents in response to a transient rise in cytosolic Ca^{2+} or ionomycin (29). A recent paper reported that lysosomal exocytosis is regulated by the bHLH-leucine zipper transcription factor EB (TFEB), and overexpression of TFEB reduces the storage materials in cell based disease models (30). Regulated exocytosis may be operative in vivo as lysosomal contents have been found in extracellular fluids, blood, and urine in certain patients with lysosomal storage diseases (35). Thus, targeting lysosomal exocytosis may be a useful strategy to mitigate the lysosomal burden in storage diseases.

In this study we show that δ-T, a minor vitamin E species, appears to exert its effect in NPC1 and Wolman fibroblasts through stimulation of lysosomal exocytosis. Translating these cell-based results to the in vivo use in animal models and patients poses a challenge with respect to its unfavorable pharmacokinetics. In comparison to α-T, which is present at 20-40 μM in human plasma – the highest among eight vitamin E isoforms, the δ-T plasma concentration in human is <1 μM (36-39). Contributing to the low plasma concentration of δ-T is its rapid oxidation by the P450 enzyme CYP4F2 (40). The brain concentration of δ-T in mice was under 1 μM after four-week treatment with 1.67 g/Kg diet per day δ-T (unpublished data). By contrast, α-T, unique among the vitamin E isoforms, is stabilized in plasma by alpha tocopherol transfer protein (41). Nonetheless, α-T is far less potent than δ-T in reducing storage in NPC1 and Wolman fibroblasts, and even with a dietary supplement, may not reach the required plasma concentration for this pharmacological effect (36,38). In the
Npc1-/mouse model, treatment with $\alpha$-T provided a functional benefit though it did not prolong survival (42). This could be due to the insufficient plasma and tissue concentration of $\alpha$-T in mouse that is needed for its cholesterol reduction effect. Therefore, the insufficient therapeutic concentrations in plasma and brain limit the use of $\delta$-T and $\alpha$-T in the animal model study as well as the clinic use to treat patients. To explore the potential effect of $\delta$-T in vivo, chemistry optimization of its pharmacokinetic properties will be required.

Although the antioxidant capacity of vitamin E is frequently thought to be its primary biological function, a number of non-antioxidant functions have been proposed. These include regulation of enzyme function, cell signaling, cell proliferation and neuroprotection (43,44). Vitamin E contains a chromanol ring with a hydroxyl group that is responsible for its antioxidant effect and a 13-carbon hydrophobic phytanyl side chain that inserts into the plasma membrane (45). $\alpha$-T, the major vitamin E isoform in human plasma, prevents apoptosis induced by 7-ketocholesterol, one of cholesterol oxidation products in neuronal cells that is markedly increased in NPC1 disease (46). $\alpha$-T has also been shown to stimulate mast cell degranulation, a secretory form of exocytosis (47). This effect of $\alpha$-T was not mediated by an upregulation of genes for proteins involved in vesicular transport (e.g., Nsf, Cplx2, Snap23, and Stx3), but through the direct interaction of $\alpha$-T with the plasma membrane (47). The pretreatment requirement of $\alpha$-T for these reported pharmacological effects may be explained by the time necessary for the incorporation of $\alpha$-T molecules into plasma membrane and for the subsequent transfer of incorporated $\alpha$-T molecules to other cellular organelles and compartments.

A specific target protein for $\delta$-T has not been found or implicated. In lysosomal storage diseases, the accumulation of lipids in lysosomes impairs cellular lipid trafficking, which could directly impact plasma membrane fluidity and dynamics. It is possible that the incorporation of $\delta$-T in the plasma membrane and the subsequent alteration of membrane physical status, such as lipid fluidity, plays a critical role in $\delta$-T’s effect on reduction of cholesterol and other lipid in the lysosome. The increase of intracellular $Ca^{2+}$ and subsequent lysosomal exocytosis by $\delta$-T support a mechanism of action mediated through the favorable change in membrane physical status. Thus, further studies on membrane biophysics and the function of membrane protein as affected by $\delta$-T are necessary to elucidate the precise mechanism of action.

Based on the above data, we have proposed a model for $\delta$-T’s pharmacological effect on the reduction of lipid accumulation in cells from patients with lysosomal storage diseases. Under normal conditions, cellular cholesterol derived from either LDL endocytosis or de novo synthesis is mobilized from lysosomes through a LAL-NPC2-NPC1 dependent pathway for distribution to the trans-Golgi and ER. We hypothesized that a minor, low-flux cholesterol trafficking pathway,
such as lysosomal exocytosis, may also exist as the cholesterol accumulation in NPC1 cells can be corrected following culture in lipoprotein-deficient serum for 5-6 days (48). Deficiency in function of the NPC1 protein disrupts the LAL-NPC2-NPC1 dependent pathway for cholesterol trafficking, resulting in impaired cholesterol efflux and lysosomal accumulation of cholesterol and other lipids. When the NPC1-deficient cells are treated with a high concentration of δ-T, the enhanced lysosomal exocytosis reduces lysosomal accumulation of cholesterol and other lipids although the defect in the LAL-NPC2-NPC1 dependent pathway is not corrected. However, given the complexity of its mechanism of action, other intracellular pathways may be involved in the vitamin E’s function that merit further study.

In conclusion, we have demonstrated that δ-T reduces cholesterol accumulation and alleviates cellular phenotypes in NPC1 and Wolman cells. Our data suggests that the pharmacological effect of δ-T may be mediated by stimulating an increase in cytosolic Ca^{2+} that enhances lysosomal exocytosis. This mechanism appears to be independent of either the mutant enzyme or the storage material, as we found that δ-T alleviated the lysosomal storage phenotype in other fibroblasts derived from patients with Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (MPS IIIB), and Tay-Sachs diseases. Although utilization of δ-T directly as a therapeutic agent is at present limited by its inability to achieve adequate plasma and brain concentrations in both animal and human, structure optimization to improve its pharmacokinetic properties and increase its plasma and tissue concentrations could lead to development of a new class of drugs for the treatment of lysosomal storage diseases.

SUPPLEMENTARY MATERIAL
Supplementary Material is available at JBC online.

ACKNOWLEDGEMENTS

This work was supported by the Intramural Research Program of the Therapeutics for rare and neglected Diseases, National Center for Advancing Translational Sciences, by the Intramural Research Program of the National Human Genome Research Institute, by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, by a grant from Ara Parseghian Medical Research Foundation, and by federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E. We thank Support of Accelerated Research for Niemann-Pick disease Type C (SOAR-NPC) for fostering a collaborative research environment and stimulating discussion. Mass spectrometry analysis was performed in the Washington University Metabolomics Facility and supported by P60 DK020579. We thank Dr. Yiannis A. Ioannou (The Mount Sinai School of Medicine) for technical assistance with the exocytosis assays and Ferri Soheilian and Christina Burks for assistance with electron microscopy.
**Abbreviations used:** α-T, alpha-tocopherol; δ-T, delta-tocopherol; bodipy-LacCer, bodipy-lactosylceramide; CLN2, Ceroid Lipoforesis, neuronal 2; ER, endoplasmic reticulum; FDA, The Food and Drug Administration; GPN, Gly-Phe β-naphthylamide; HPBCD, 2-hydroxypropyl-β-cyclodextrin; HDAC, histone deacetylases; HDL, high-density lipoprotein; HMG-CoA reductase, 3-hydroxy-3-methyl-glutaryl-CoA reductase; LAL, lysosomal acid lipase; LDL, low-density lipoprotein; MPSIIIB, Mucopolysaccharidosis type IIIB; MSCs, mesenchymal stem cells; NPA, Niemann-Pick disease type A; NPC, Niemann-Pick disease type C; PBS, phosphate Buffer saline.

### FIGURE LEGENDS

**FIGURE 1.** Chemical structures of eight isoforms of vitamin E and EC_{50} values for reduction of cholesterol accumulation in NPC1 and Wolman fibroblasts. (A) The difference between tocotrienols and tocopherols is that tocotrienols have three double bonds in the phytol side chain while tocopherols do not. The EC_{50} values in NPC1 fibroblasts were measured for the reduction of cellular unesterified cholesterol, whereas the EC_{50} values in Wolman fibroblasts were determined for the reduction of total cellular cholesterol (unesterified cholesterol and cholesteryl ester). (B) Cellular unesterified cholesterol and (C) Cellular cholesteryl ester were decreased by 40 μM δ-T or 80 μM α-T in two NPC1 cell lines (GM03123 and NPC25) measured by the LC-MS method. Results are showed as mean of three experiments with SD.

**FIGURE 2.** δ-T and α-T reduced cholesterol accumulation phenotypes in NPC1 and Wolman fibroblasts. (A) Filipin staining of unesterified cholesterol was reduced in NPC1 cells and (B) Nile Red staining of neutral lipids (cholesteryl ester and triglyceride) was decreased in Wolman fibroblasts by 40 μM δ-T or 80 μM α-T. The filipin stained cells were co-stained with CellMask, a plasma membrane dye. (C) Mistrafficking of bodipy-LacCer in NPC1 fibroblasts was corrected by 40 μM δ-T.

**FIGURE 3.** δ-T and α-T reduced cellular acidic compartments and decreased pathological lysosomal inclusions in NPC1 and Wolman cells. (A) The LysoTracker dye staining (for acidic compartments) was reduced in both NPC1 and Wolman cells by 40 μM δ-T or 80 μM α-T. The LysoTracker-red staining images were merged with Hoechst nuclei dye staining. (B) Electron micrographs of thin sections of NPC1 and Wolman fibroblasts were compared with control fibroblasts. The inset in the untreated NPC1 fibroblast shows in detail the lamellated and osmophilic structures in lysosomes (bar = 1 μm) which were significantly reduced by the treatment with 40 μM δ-T. In the untreated Wolman fibroblasts, the white arrowheads mark the typical elongated and cleft-shaped lipid droplets observed in lysosomes and which were alleviated by the treatment with 40 μM δ-T.

**FIGURE 4.** δ-T increased cholesterol efflux and intracellular Ca^{2+} concentration. (A) ^3H-cholesterol efflux carried out by addition of HDL in medium was enhanced by 40 μM δ-T and 80 μM α-T in the BHK cells, respectively. The efflux of ^3H-cholesterol was greatly augmented by the expression of ABCA1 transporters in BHK cells, which was further enhanced by δ-T and α-T. (B) Intracellular Ca^{2+} increased in the presence of 75 μM δ-T or 250 μM δ-T in both NPC1 (see D for the calcium tracers) and Wolman (see E for the calcium tracers) fibroblasts. (C) δ-T reduced the impairment of lysosomal Ca^{2+}
release in NPC1 cells. The NPC1 fibroblasts exhibited reduced lysosomal Ca\(^{2+}\) release stimulated by 200 nM Gly-Phe β-naphthylamide (GPN), which was partially corrected by a 24 hr pretreatment with 40 µM δ-T. Data Results showed are mean of three experiments; error bar represent SD. (F) Images of endocytic vesicles indicated by a fluorescent pHrodo\(^{TM}\) dextran dye in NPC1 and Wolman fibroblasts. The treatment with 40 µM δ-T or 80 µM α-T did not alter the fluorescence intensity in the endocytic vesicles in these cells, indicating that both compounds do not affect the endocytosis in NPC1 and Wolman fibroblasts.

FIGURE 5. **Lysosomal exocytosis in δ-T and α-T treated NPC1 and Wolman disease fibroblasts.** Lysosomal exocytosis was enhanced by δ-T and α-T in NPC1 (A) and Wolman (B) fibroblasts as well as in the control fibroblasts (C). After a 24 hr pretreatment with 40 µM δ-T or 80 µM α-T, the activity of HEXB (a lysosomal enzyme) in extracellular medium significantly increased in all three cell types. The data shown are the mean of three experiments and the error bars represent SD. (D) Secretion of exosomes in δ-tocopherol treated cells measured by Western blot analysis of flotillin 2 in the culture media of control fibroblasts. The upper panel exhibits the bands detected by an anti-flotillin 2 antibody in exosome fractions incubated with buffer, 2% HPBCD (a positive control), 160 µM δ-tocopherol or 1 µM Ionomycin. Equal loading was normalized by GAPDH levels in the cell lysate (lower panel). (E) Electron micrographs of untreated NPC1 (top left) and Wolman (top right) cells versus treated NPC1 (bottom left) and Wolman (bottom right) cells show that the lysosomal storage materials in 40 µM δ-T not only decreased but also moved closer to the plasma membrane in overall distribution in the cell (Bar = 5 µm). Insets show 5x magnified areas with vesicles close to the plasma membrane.

FIGURE 6. **Effect of δ-T on ultrastructural pathology in lysosomal storage disorder fibroblasts.** Treatment with 40 µM δ-T reduced lysosomal size and corrected lysosomal inclusions in patient fibroblasts of Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (MPS IIIB), and Tay-Sachs diseases. Images of LysoTracker staining in the absence of (A) or presence of (B) 40 µM δ-T treatment. LysoTracker-red staining was significantly reduced after the treatment with δ-T, consistent with decrease of the acidic compartment size. Electron micrographs of patient fibroblasts in the absence of (C) or presence of δ-T (D) (bar = 2 µm in main panels and = 500 nm in insets). Typical large osmiophilic, mono- and multinuclear multilamellar bodies are observed in Niemann-Pick Disease type A (NPA), Tay-Sachs, and Farber disease cells; similar but smaller and usually multinuclear multilamellar bodies are observed in Batten (CLN2), Sanfilippo type B (MPS IIIB), and Fabry disease cells (see insets for detail). The pathological phenotypes in ultrastructure were significantly alleviated after the treatment with 40 µM δ-T in all these six types of patient fibroblasts.

REFERENCES

Fig. 1. Chemical structures of the eight isoforms of vitamin E and EC50 values for reduction of cholesterol accumulation in NPC1 and Wolman fibroblasts. (A) The difference between tocotrienols and tocopherols is that tocotrienols have three double bonds in the phytol side chain while tocopherols do not. The EC50 values in NPC1 fibroblasts were measured for the reduction of cellular unesterified cholesterol, whereas the EC50 values in Wolman fibroblasts were determined for the reduction of total cellular cholesterol (unesterified cholesterol and cholesteryl ester). (B) Cellular unesterified cholesterol and (C) Cellular cholesteryl ester were decreased by 40 µM δ-T or 80 µM α-T in two NPC1 cell lines (GM03123 and NPC25) measured by the LC-MS method. Results are showed as mean of three experiments with SD.
Fig. 2. δ-T and α-T reduced cholesterol accumulation phenotypes in NPC1 and Wolman fibroblasts. (A) Filipin staining of unesterified cholesterol was reduced in NPC1 cells and (B) Nile Red staining of neutral lipids (cholesteryl ester and triglyceride) was decreased in Wolman fibroblasts by 40 µM δ-T or 80 µM α-T. The filipin stained cells were co-stained with the CellMask dye that stained plasma membrane. (C) Mistrafficking of bodipy-LacCer in NPC1 fibroblasts was corrected by 40 µM α-T.
A. LysoTracker staining

B. Electron microscopic images

FIGURE 3. δ-T and α-T reduced cellular acidic compartments and decreased pathological lysosomal inclusions in NPC1 and Wolman cells. (A) The LysoTracker dye staining (for acidic compartments) was reduced in both in both NPC1 and Wolman cells by 40 µM δ-T or 80 µM α-T. The LysoTracker-red staining images were merged with Hoechst nuclei dye staining. (B) Electron micrographs of thin sections of NPC1 and Wolman fibroblasts were compared with control fibroblasts. The inset in the untreated NPC1 fibroblast shows in detail the lamellated and osmophilic structures in lysosomes (bar = 1 µm) which were significantly reduced by the treatment with 40 µM δ-T. In the untreated Wolman fibroblasts, the white arrowheads mark the typical elongated and cleft-shaped lipid droplets observed in lysosomes and which were alleviated by the treatment with 40 µM δ-T.
FIGURE 4. δ-T increased cholesterol efflux and intracellular Ca^{2+} concentration. (A) ^3^H-cholesterol efflux carried out by addition of HDL in medium was enhanced by 40 µM δ-T and 80 µM α-T in the BHK cells, respectively. The efflux of ^3^H-cholesterol was greatly augmented by the expression of ABCA1 transporters in BHK cells, which was further enhanced by δ-T and α-T. (B) Intracellular Ca^{2+} increased in the presence of 75 µM δ-T or 250 µM δ-T in both NPC1 (see D for the calcium tracers) and Wolman (see E for the calcium tracers) fibroblasts. (C) δ-T reduced the impairment of lysosomal Ca^{2+} release in NPC1 cells. The NPC1 fibroblasts exhibited reduced lysosomal Ca^{2+} release stimulated by 200 nM Gly-Phe β-naphthylamide (GPN), which was partially corrected by a 24 hr pretreatment with 40 µM δ-T. Data Results showed are mean of three experiments; error bar represent SD. (F) Images of endocytic vesicles indicated by a fluorescent pHrodo™ dextran dye in NPC1 and Wolman fibroblasts. The treatment with δ-T or α-T did not alter the fluorescence intensity in the endocytic vesicles in these cells, indicating that both compounds do not affect the endocytosis in NPC1 and Wolman fibroblasts.
FIGURE 5. **Lysosomal exocytosis in δ-T and α-T treated NPC1 and Wolman disease fibroblasts.** Lysosomal exocytosis was enhanced by δ-T and α-T in NPC1 (A) and Wolman (B) fibroblasts as well as in the control fibroblasts (C). After a 24 hr pretreatment with 40 μM δ-T or 80 μM α-T, the activity of HEXB (a lysosomal enzyme) in extracellular medium significantly increased in all three cell types. The data shown are the mean of three experiments and the error bars represent SD. (D) Secretion of exosomes in δ-tocopherol treated cells measured by Western blot analysis of flotillin 2 in the culture media of control fibroblasts. The upper panel exhibits the bands detected by an anti-flotillin 2 antibody in exosome fractions incubated with buffer, 2% HPBCD (a positive control), 160 μM δ-tocopherol or 1 μM Ionomycin. Equal loading was normalized by GAPDH levels in the cell lysate (lower panel). (E) Electron micrographs of untreated NPC1 (top left) and Wolman (top right) cells versus treated NPC1 (bottom left) and Wolman (bottom right) cells show that the lysosomal storage materials in 40 μM δ-T not only decreased but also moved closer to the plasma membrane in overall distribution in the cell (Bar = 5 μm). Insets show 5x magnified areas with vesicles close to the plasma membrane.
Fig. 6. Effect of δ-T on ultrastructural pathology in lysosomal storage disorder fibroblasts. Treatment with 40 μM δ-T reduced lysosomal size and corrected lysosomal inclusions in patient fibroblasts of Batten (CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (MPS IIIB), and Tay-Sachs diseases. Images of LysoTracker staining in the absence of (A) or presence of (B) 40 μM δ-T treatment. LysoTracker-red staining was significantly reduced after the treatment with δ-T, consistent with decrease of the acidic compartment size. Electron micrographs of patient fibroblasts in the absence of (C) or presence of δ-T (D) (bar = 2 μm in main panels and = 500 nm in insets). Typical large osmiophilic, mono- and multinuclear multilamellar bodies are observed in Niemann-Pick Disease type A (NPA), Tay-Sachs, and Farber disease cells; similar but smaller and usually multinuclear multilamellar bodies are observed in Batten (CLN2), Sanfilippo type B (MPS IIIB), and Fabry disease cells (see insets for detail). The pathological phenotypes in ultrastructure were significantly alleviated after the treatment with 40 μM δ-T in all these six types of patient fibroblasts.
Authors are urged to introduce these corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of these corrections as prominently as they carried the original abstracts.
δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders
Miao Xu, Ke Liu, Manju Swaroop, Forbes D. Porter, Rohini Sidhu, Sally Firnkes, Daniel S. Ory, Juan J. Marugan, Jingbo Xiao, Noel Southall, William J. Pavan, Cristin Davidson, Steven U. Walkley, Alan T. Remaley, Ulrich Baxa, Wei Sun, John C. McKew, Christopher P. Austin and Wei Zheng

J. Biol. Chem. published online October 3, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.357707

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/10/03/M112.357707.DC1

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2012/10/03/jbc.M112.357707.full.html#ref-list-1